<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633762</url>
  </required_header>
  <id_info>
    <org_study_id>ERA 2012</org_study_id>
    <nct_id>NCT01633762</nct_id>
  </id_info>
  <brief_title>Eradication of Gut Microbiota</brief_title>
  <acronym>ERA</acronym>
  <official_title>Eradication of Gut Microbiota - Effects on Postprandial Gut Hormone Secretion, Glucose Metabolism, Bone Metabolism and Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of clinical microbiology, Rigshospitalet, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effect of eradication of gut microbiota on 1) glucose
      metabolism including postprandial plasma responses of the incretin hormones GIP and GLP-1,
      insulin, C-peptide and glucagon, 2) metabolomic profiles and resting energy expenditure (REE)
      3) appetite, satiety, food intake, gastric emptying and gall bladder emptying, 4) levels of
      markers of bone formation and resorption as well as serotonin, 5) markers of systemic
      inflammation, and 6) on the (prospective) composition of bacteria in faeces, blood and
      saliva. Thus, the overall objective is to provide detailed knowledge on the physiological
      role of gut microbiota combined with bioinformatic analyses of the functional implications of
      changes in bacteria composition on the level of both species and phylum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in postprandial GLP-1 secretion</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma level of GLP-1 at baseline and during a 4 hour-meal test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in postprandial insulin/c-peptide secretion</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma level of insulin/C-peptide at baseline and during a 4 hour-meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in postprandial glucose levels</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma level of glucose at baseline and during a 4 hour-meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in postprandial GLP-2, glucagon, PYY, oxyntomodulin, gastrin, CCK, GIP, leptin, adiponectin and ghrelin secretion</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma levels of GLP-2, glucagon, PYY, oxyntomodulin, gastrin, CCK, GIP, leptin, adiponectin and ghrelin at baseline and during a 4 hour-meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in markers of bone formation and resorption</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>fasting plasma levels of osteocalcin, P1NP, CTX, 1CTP, sklerostin and serotonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut microbiome composition</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in markers of systemic inflammation</measure>
    <time_frame>0, 4, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma levels of high sensitive CRP, LPBP, TNF-alfa, IL-6 and PAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in glycated hemoglobin (HbA1c)</measure>
    <time_frame>42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma level of glycated hemoblobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body weight</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in basal metabolic rate and respiratory quotient</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>indirect calorimetry measurements (210 minutes postprandial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in gastric emptying</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>1,5 grams of paracetamol will be added to a standardized meal, plasma paracetamol will be measured at baseline and succeeding 4 hours postprandial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in gall bladder emptying</measure>
    <time_frame>0, 4 and 42 days after antibiotic eradication of gut bacteria</time_frame>
    <description>ultrasonic determination of gall bladder dimensions at baseline and during a 4 hour-meal test (expressed as gall bladder ejection fraction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appetite, satiety and food intake</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>the impact of eradication on alimentary processes and appetite regulation will be measured using questionnaires and food intake measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in ketone metabolism</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>measurement of fasting plasma beta-hydroxybutyrate level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in bile acid deconjugation</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>measurement of feces bile acid (conjugated and deconjugated) concentration to study the effect of gut microbiome presence on bile acid deconjugation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in plasma lipid levels</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>fasting plasma levels of triglyceride, VLDL, LDL, HDL, total cholesterol, in addition: measurements of free fatty acids during a 4 hour meal 0, 4 and 42 days after eradication (not on day 8 and 180)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiome in blood, urine and saliva</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>measurements on bacteria or bacterial components in blood, urine and saliva to study the effects of gut eradication on blood, urine and saliva microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects of the used antibiotics</measure>
    <time_frame>up to 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>standardized questionaries regarding gastointestinal function are filled out at each study visit (0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in metabolomic profile</measure>
    <time_frame>0, 4, 8, 42 and 180 days after antibiotic eradication of gut bacteria</time_frame>
    <description>plasma and urine samples for metabolomic analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <condition>Osteoporosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>meropenem, gentamicin, vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem, gentamicin, vancomycin (together)</intervention_name>
    <description>4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin &quot;Hospira&quot;), powder for concentrate; gentamycin 40 mg (&quot;Hexamycin®&quot;), solution; meropenem 500 mg (Meropenem &quot;Hospira&quot;), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)</description>
    <arm_group_label>meropenem, gentamicin, vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  danish caucasian ethnicity

          -  informed consent

          -  normal fasting plasma glucose

          -  normal HbA1c (&lt;6 %)

          -  normal serum lipids

          -  normal thyroid function

          -  normal danish diet

          -  non-smoking

          -  normal stool habits

        Exclusion Criteria:

          -  known bone disease

          -  liver disease (ALAT or ASAT &gt;2 upper normal value)

          -  kidney disease (serum creatinine &gt;130 μM)

          -  anaemia

          -  BMI &lt;18.5 kg/m2 or BMI &gt;25 kg/m2

          -  known gastrointestinal disease (including prior bariatric surgery,lactose
             -intolerance, celiac disease, inflammatory bowel disease) or known familial
             disposition for lactose intolerance, celiac disease, inflammatory bowel disease

          -  antibiotic treatment within 6 months prior to study including malaria prophylaxis

          -  medication which cannot be on hold for the study period

          -  contraindications against/allergy towards the used antibiotics (including prior
             allergic reactions related to beta-lactam antibiotics, aminoglycosides or vancomycin)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian H Mikkelsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Diabetes Research Unit, Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Kristian Hallundbuk Mikkelsen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

